Job for Pharma Professionals at HLL Lifecare Limited

HLL Lifecare Limited is a Govt. of India Healthcare products manufacturing and services Company based in Thiruvananthapuram, Kerala, India under the Union Ministry of Health and Family Welfare, HLL is a global leader in the area of contraceptives, hospital products and healthcare services.

With 7 manufacturing units, 7 subsidiary companies, 22 regional offices and having presence in more than 115 countries, HLL is positioned as a total healthcare solution provider catering to the well-being of the society at large.

Post :SCIENTIST E3

Job Description
The job profile for the position is as under:
1. Development of drug delivery systems/ implants for regulated markets

2. Preparation of dossier for regulatory submissions for obtaining marketing clearance in regulated markets

3. Scale up and Technology Transfer

4. Meeting audit as per regulatory requirements

Candidate Profile

Maximum Age: 40 years as on 01.05.2021
Consolidated pay range (For Fixed Term Contract engagement): 35,000 –65,000/- (Senior Manager (E3) per month.

(The consolidated pay will be fixed within the pay range depending on the qualification, experience and the current pay drawn by the candidate. The consolidated pay will be inclusive of all allowances and benefits).

Educational Qualification:

Essential: PhD in Pharmaceutics / M.Pharm Pharmaceutics

Essential: Minimum 5 years post qualification for PhD/ Minimum 8 Years post qualification experience for M.Pharm
Desirable: Patents, Technology transfers in novel drug delivery systems

General Conditions:
• SC/ST/OBC/PwD candidates will be eligible for relaxation as per Government of India directives.
• Canvassing in any form will be a disqualification.
Location :  Anywhere in India
Last Date : 26.05.2021

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’